 | Galectin Therapeutics (NASDAQ:GALT) Shares Up 5.1%
americanbankingnews.com - August 5 at 9:17 PM |
 | Is Galectin Therapeutics, Inc.'s (NASDAQ:GALT) Shareholder Ownership Skewed Towards Insiders?
finance.yahoo.com - August 3 at 1:21 PM |
| Galectin Therapeutics (NASDAQ:GALT) Stock Price Crosses Above 200-Day Moving Average of $2.52
www.americanbankingnews.com - July 29 at 3:56 AM |
| Analysts Expect Galectin Therapeutics Inc. (NASDAQ:GALT) Will Post Earnings of -$0.09 Per Share
www.americanbankingnews.com - July 21 at 4:38 PM |
 | Intercept's Pain Is Galectin's Gain: Clinical Outcomes In NASH Are Crucial
seekingalpha.com - July 7 at 9:35 AM |
 | Galectin Therapeutics, Inc. and Providence Cancer Institute Receive Patent on the Use of Belapectin (GR-MD-02) in Cancer
www.bloomberg.com - July 6 at 11:33 PM |
| Galectin launches new study of lead drug in NASH
seekingalpha.com - June 30 at 1:18 PM |
| Galectin Therapeutics Announces Commencement of Patient Enrollment of the Adaptively-Designed Phase 2b/3 Trial of Belapectin in NASH Cirrhosis
finance.yahoo.com - June 30 at 1:18 PM |
| UPDATE -- Galectin Therapeutics Announces Commencement of Patient Enrollment of the Adaptively-Designed Phase 2b/3 Trial of Belapectin in NASH Cirrhosis
finance.yahoo.com - June 30 at 1:18 PM |
| Galectin Therapeutics' Shares March Higher, Can It Continue?
finance.yahoo.com - May 22 at 12:37 PM |
|
 | GALT Galectin Therapeutics Inc. Common Stock
www.nasdaq.com - May 20 at 11:43 PM |
| Galectin Therapeutics EPS beats by $0.03
seekingalpha.com - May 11 at 5:29 PM |
| Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2020, and Provides Business Update
finance.yahoo.com - May 11 at 5:29 PM |
| Companies Like Galectin Therapeutics (NASDAQ:GALT) Are In A Position To Invest In Growth
finance.yahoo.com - May 4 at 5:00 PM |
| Galectin Therapeutics Submits Seamless Adaptively-Designed Phase 2b/3 NASH-RX Protocol in NASH Cirrhosis
finance.yahoo.com - April 30 at 4:30 PM |
| Galectin Therapeutics Update on the Impact of COVID-19
finance.yahoo.com - April 2 at 4:06 PM |
 | Galectin Therapeutics Inc.
www.barrons.com - March 21 at 11:56 PM |
| Galectin Therapeutics EPS misses by $0.04
seekingalpha.com - March 16 at 9:47 AM |
| Galectin Therapeutics Reports Fiscal 2019 Financial Results and Provides Business Update
finance.yahoo.com - March 16 at 9:47 AM |
| Galectin Therapeutics Inc. Common Stock (GALT) Institutional Holdings | Nasdaq
www.nasdaq.com - February 20 at 7:41 PM |
| Galectin Therapeutics Appoints Seasoned Biopharmaceutical Executive Pol F. Boudes, M.D. as Chief Medical Officer
finance.yahoo.com - February 20 at 9:40 AM |
 | Galectin Therapeutics' President and CEO Dr. Harold Shlevin to Present at the 3rd Global NASH Congress 2020
www.marketwatch.com - February 4 at 1:08 PM |
| Are Insiders Buying Galectin Therapeutics, Inc. (NASDAQ:GALT) Stock?
finance.yahoo.com - February 4 at 1:08 PM |
| Galectin Therapeutics’ President and CEO Dr. Harold Shlevin to Present at the 3rd Global NASH Congress 2020
finance.yahoo.com - February 4 at 8:08 AM |
| Is Galectin Therapeutics Inc. (GALT) Going to Burn These Hedge Funds?
finance.yahoo.com - December 20 at 10:32 PM |
| Galectin Therapeutics: An Even Better Buy As It Hits 52-Week Lows
seekingalpha.com - December 12 at 5:50 PM |
| Galectin Therapeutics' Phase 2 NASH Cirrhosis Clinical Trial Results on Belapectin (GR-MD-02) Published in Gastroenterology
www.marketwatch.com - December 9 at 9:23 AM |
| Galectin Therapeutics’ Phase 2 NASH Cirrhosis Clinical Trial Results on Belapectin (GR-MD-02) Published in Gastroenterology
finance.yahoo.com - December 9 at 9:23 AM |
|
| Galectin Therapeutics Plans Adaptively Designed Phase 3 NASH-RX Clinical Trial in NASH Cirrhosis
finance.yahoo.com - December 5 at 2:43 PM |
| Galectin Therapeutics to Webcast Corporate Update on December 4, 2019, after Annual Meeting of Stockholders
finance.yahoo.com - November 26 at 8:39 AM |
 | Galectin Therapeutics to Present at Anti-Fibrotic Drug Development (AFDD) Summit
www.benzinga.com - November 18 at 4:43 PM |
| Galectin Therapeutics EPS beats by $0.05
seekingalpha.com - November 12 at 8:55 AM |
| Galectin Therapeutics Reports Q3 2019 Financial Results
finance.yahoo.com - November 12 at 8:55 AM |
| Galectin Therapeutics Reaches Agreement with Siemens Healthineers to Collaborate on NASH and Liver Fibrosis
finance.yahoo.com - November 11 at 1:26 PM |
| Additional Ad Hoc Analysis of ELF Data from Galectin Therapeutics NASH-CX Phase 2 Clinical Trial to be Highlighted in Poster Presentation at the 2019 AASLD Liver Meeting
finance.yahoo.com - November 5 at 8:37 AM |
| We're Not Worried About Galectin Therapeutics's (NASDAQ:GALT) Cash Burn
finance.yahoo.com - October 28 at 1:45 PM |
| We're Not Worried About Galectin Therapeutics's (NASDAQ:GALT) Cash Burn
finance.yahoo.com - October 28 at 1:45 PM |
| Galectin Therapeutics and Providence Cancer Institute nabs new patent in U.S.
seekingalpha.com - September 17 at 11:34 AM |
| Galectin Therapeutics and Providence Cancer Institute nab new patent in U.S.
seekingalpha.com - September 17 at 11:34 AM |
| Galectin Therapeutics, Inc. and Providence Cancer Institute Receive Patent on the Use of Belapectin (GR-MD-02) in Cancer Immunotherapy
finance.yahoo.com - September 17 at 11:34 AM |
| Need To Know: Galectin Therapeutics, Inc. (NASDAQ:GALT) Insiders Have Been Buying Shares
finance.yahoo.com - August 27 at 10:27 PM |
| Galectin holders file to offer up to 1.7M shares
seekingalpha.com - August 10 at 5:38 AM |
| Galectin Therapeutics Submits Phase 3 NASH-RX Protocol in Nash Cirrhosis to FDA
finance.yahoo.com - August 5 at 8:53 AM |
| Galectin Therapeutics Raises $44.5 Million in Rights Offering and $2.5 Million from Warrant Exercise
finance.yahoo.com - May 28 at 9:32 AM |
| What Type Of Shareholder Owns Galectin Therapeutics, Inc.'s (NASDAQ:GALT)?
finance.yahoo.com - May 27 at 5:41 PM |
| Galectin sets lower price in rights offering
seekingalpha.com - May 24 at 8:00 AM |
| Galectin Therapeutics Reports Alternate Price of Common Stock in Rights Offering
finance.yahoo.com - May 23 at 7:43 PM |
| Galectin Therapeutics: Primed For Takeoff After The Rights Offering And New Clinical Evidence
seekingalpha.com - May 15 at 5:49 PM |
| Galectin Therapeutics misses by $0.06
seekingalpha.com - May 10 at 9:57 AM |
| Galectin Therapeutics Reports Q1 2019 Financial Results and Provides Business Update
finance.yahoo.com - May 10 at 9:57 AM |
